Vunakizumab-induced severe ulcerative colitis during treatment of psoriatic arthritis: a case report and literature review
BackgroundInterleukin-17A (IL-17A) inhibitors are effective therapies for psoriasis (PsO) and psoriatic arthritis (PsA), yet they may induce or exacerbate inflammatory bowel disease (IBD). Vunakizumab is a novel humanized anti-IL-17A monoclonal antibod…